NBIX•benzinga•
Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $165
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 6, 2025 by benzinga